Sleeping Aids Providing Comfort to Sleep Apnea Patients

 The American Sleep Apnea Association says that at present, around 22 million people in the U.S. suffer from sleep apnea. Among these, around 80% of cases of severe and moderate obstructive sleep apnea (OSA) remain undiagnosed. OSA can affect infants as well as adults; however, it is most frequent among men over 40 years. This disorder is highly prevalent among overweight or obese men. Thus, the surging cases of sleep disorders, such as OSA and insomnia, will create a huge requirement for sleeping aids in the coming years.

Browse detailed report with COVID-19 impact analysis on Sleeping Aids Market Report

In recent years, BRAEBON Medical Corporation, Takeda Pharmaceutical Company Limited, Löwenstein Medical GmbH & Co. KG, Natus Medical Incorporated, GlaxoSmithKline plc, Merck & Co. Inc., ResMed Inc., and Koninklijke Philips N.V. have been focusing on the production of sleep apnea devices, mattress and pillows, and medication and offering sleep laboratory services. In contemporary times, mattresses and pillows are being preferred over other sleeping aids due to their cost-effectiveness and availability in wide varieties. These products are used to comfort and treat patients suffering from insomnia, sleep apnea, narcolepsy, restless leg syndrome (RLS), and sleepwalking.

Currently, sleeping aids manufacturers are engaging in product launches and partnerships and collaborations to reach out to a greater number of customers. For instance, in September 2019, Koninklijke Philips N.V. introduced its expanded SmartSleep suite of solutions in the U.S. These solutions assist users in addressing an array of sleep issues, ranging from difficulty in falling asleep to snoring. Furthermore, in January 2020, SleepScore Labs partnered with Serta Simmons Bedding LLC (SSB) to explore the effects of sleeping on the iComfort by Serta CF4000 mattress and its ability to offer restful and comfortable sleep.

Whereas, the Asia-Pacific (APAC) sleeping aids market is expected to progress at the highest rate in the foreseeable future. This will be due to the increasing consumption of sleeping pills, booming geriatric population, and rising burden of sleeping disorders. According to the United Nations Population Fund (UNFPA), the population of people aged 60 years or above in the region will reach around 1.3 billion by 2050. Moreover, the low manufacturing cost of the products, owing to the easy availability of raw materials and labor, will support the market growth in the region.

Thus, the mounting cases of sleeping disorders and escalating demand for sleeping pills will fuel the adoption of sleeping aids.

Read More

Increasing Research Activities Drive Development of Catalog Peptides

Every year, over 9.5 million people die of cancer each year, according to the World Health Organization (WHO). This is because either patients are diagnosed in later stages, or the drugs aren’t able to target tumors that well. A lot of cancers are formed due to the disruption in the pathways activated by peptides, which are essentially short chains of amino acids; a peptide of more than 50 amino acids is known as a protein. Since the establishment of the fact that protein pathway disruption is a potential cause of cancer, extensive research and development (R&D) has been put in to remedy this.

Browse detailed report with COVID-19 impact analysis on Catalog Peptides Market Competitive Landscape

Thus, with the rising prevalence of cancer and fruitful R&D, the catalog peptides market is predicted to grow from $238.4 million in 2018 to $332.1 million by 2024, at a 5.8% CAGR during 2019–2024 (forecast period). The term catalog peptide refers to the artificially synthesized peptide drugs which are readily available with biotechnology and pharmaceutical companies, as opposed to those that are customized as per user preference and the specific application.

Presently, North America makes the largest contribution to the catalog peptides market, owing to the presence of a number of biopharmaceutical companies, increasing R&D investments for widening the application area of such products, and adoption of improved technologies for manufacturing. Within the region, the U.S. consumes such drugs in higher amounts, owing to its increasing incidence of chronic diseases, especially cancer. Moreover, numerous drugs are receiving approvals from the Food and Drug Administration, which is leading to their rising availability for the treatment of various diseases.

Hence, with the rising R&D activities and prevalence of cancer, the demand for catalog peptides will also grow.

Read More

Anti-Aging and Skin Rejuvenation Energy-Based Aesthetic Devices Market Set to Prosper in Future

The global anti-aging and skin rejuvenation energy-based aesthetic devices market is expected to exhibit rapid advancement in the future years, as per the forecast of P&S Intelligence, a market research firm based in India. The market is being driven by the rising geriatric population in several countries, thriving medical tourism industry, soaring public awareness of anti-aging and skin rejuvenation energy-based aesthetic devices, rapid technological advancements and innovations in these devices, and the surging popularity of minimally invasive aesthetic treatment procedures across the world.

The growing geriatric population is one of the key factors fueling the progress of the market. This is because of the fact that increasing age leads to the loss of fibrous tissue and decreased glandular and vascular network in the skin layers, which in turn, results in the formation of wrinkles and causes skin sagging, dryness, and pigmentary alteration. The usage of anti-aging products significantly reduces the occurrence of these skin problems as these products revitalize and tighten the skin and give it a younger look. 

Browse report overview and detailed TOC on Anti-Aging and Skin Rejuvenation Energy-Based Aesthetic Devices Market Demand

As per a report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of the people in the age bracket 60 years or above would rise to 437 million in China, 58 million in Brazil, 107 million in the U.S., and 324 million in India by 2050. The increasing population of geriatric people in these countries will massively push up the sales of these anti-aging devices in the future years. 

Geographically, the anti-aging and skin rejuvenation energy-based aesthetic devices market is predicted to register rapid progress in North America during the coming years. In addition to this region, the market is also predicted to record significant growth in Europe in the upcoming years. The main factors responsible for the expansion of the market in these regions are the existence of numerous prominent players, growing geriatric population, and the increasing consciousness amongst the people about looks and appearance.

Thus, it can be said without any doubt that the market will demonstrate huge growth in the forthcoming years, primarily due to the rising geriatric population and the increasing popularity of anti-aging devices and treatment procedures across the world. 

Read More

Sales of Home-Use Insulin Delivery Devices Soaring in an Ageing World

The growing incidence of diabetes is driving the demand for home-use insulin delivery devices. According to the World Health Organization (WHO), 422 million people all over the world are currently suffering from diabetes. Furthermore, the organization reported that diabetes claims the lives of 1.6 million people every year. Besides the rising prevalence of diabetes, the mushrooming population of geriatric people is also fueling the demand for home-use insulin delivery devices across the world. 

Access Report Summary - Home-Use Insulin Delivery Devices Market Growth and Demand Forecast

Apart from the aforementioned factors, the rapid technological advancements being made in insulin delivery devices are also propelling their popularity globally. Insulin inhalers, insulin pumps, and insulin pens have several advantages such as the ability to administer the required dosage of insulin accurately, thereby assisting in maintaining the normal level of insulin in the body. Moreover, it is less time consuming to administer insulin via insulin pens in comparison to insulin administration via syringes. The other advantages of these pens are the ability to minimize the risk of inaccurate dose administration and greater patient acceptability.

This was because of the ease of administering insulin, rapid advancements made in the insulin pen technology, and the integration of the internet of things and smartphones in them. When distribution channel is taken into consideration, the home-use insulin delivery devices market is classified into e-commerce, diabetes clinics/centers, and pharmacies. Amongst these, the e-commerce category is predicted to register the fastest growth in the market in the coming years. This is ascribed to the various offers and discounts that are being provided by the e-commerce platforms. Additionally, these platforms provide the details of the products of various brands, which allows customers to make price and feature comparisons. 

Geographically, the home-use insulin delivery devices market was dominated by North America in 2020, as per the observations of the market research firm, P&S Intelligence. This was because of the high incidence of lifestyle diseases such as obesity and diabetes, growing public awareness about the importance of proper diabetes management, and surging healthcare expenditure in the regional countries. Additionally, the presence of a large obese population also contributed massively toward the high sales of home-use insulin delivery devices in the region, as obesity is a major risk factor for diabetes. 

Read More

Explosive Growth Expected in APAC Gene Therapy Market During 2021–2030

 The Asia-Pacific (APAC) gene therapy market revenue stood at $349.1 million in 2020, and it is predicted to rise to $6,931.5 million by 2030. The market will also exhibit a CAGR of 36.8% between 2021 and 2030, as per the estimates of the market research firm, P&S Intelligence. The factors driving the market expansion are the surging gene therapy activities, rising incidence of chronic diseases, and increasing number of clinical trials being conducted with positive results across the region. 

Read the full report - APAC Gene Therapy Market

As per the data, the company’s engineered RPGR constructs and proprietary adeno-associated viruses (AAV) vector were well tolerated and had various beneficial effects of the disease markers in a canine model of XLRP. Additionally, the treated patients showed massive improvements in their visual functions. Besides the positive results of the clinical trials, the increasing therapy development activities being carried out by various private and public research companies are also driving the expansion of the Asia-Pacific gene therapy market.

Between these, the in-vivo category held the larger share in the market between 2015 and 2020, primarily due to the high efficacy and less difficulty associated with this gene therapy method. When vector type is taken into consideration, the APAC gene therapy market is classified into herpes simplex virus (HSV), lentivirus, non-viral, and adenovirus categories. Out of these, the adenovirus category is predicted to exhibit the fastest growth in the market in the coming years.

The APAC gene therapy market is expected to exhibit the highest growth rate in China in the upcoming years. This is attributed to the increasing strategic development activities being announced by the key players and the growing prevalence of rare diseases and cancer in the country. As per an article published in the South China Morning Post in April 2019, around 20 million people are diagnosed with rare diseases in mainland China. 

Read More

Synthesis of Custom Peptides Boosting Drug Development

Presently, the pharmaceutical sector is synthesizing peptides through multiple processes, on account of technological advancements. In earlier times, peptides were produced with the help of natural sources. For instance, adrenocorticotropic hormone (ACTH) was developed from porcine and bovine pituitary, and insulin was derived from bovine and canine pancreas. These manufacturing processes were time consuming and resulted in low production. However, with innovations in technology, biopharmaceutical companies have started creating synthetic peptides like vasopressin, leuprorelin, oxytocin, and octreotide with the help of solid-phase peptide synthesis (SPPS), hybrid and recombinant technology, and solution-phase peptide synthesis (SPS) technologies.

Browse In-depth Competitive landscape of the Customized Peptide Synthesis Market 

Moreover, the surging participation of private and public research institutes in synthetic biology research will accelerate the customized peptide synthesis market at a CAGR of 6.4% during 2019–2024. The market stood at $268.8 million in 2018, and it has the potential to reach $390.0 million by 2024. The increasing participation of research entities will amplify the funding for the development of advanced and innovative bio-based products, to deal with the global health challenges. These research and development (R&D) activities are essentially aimed at producing better drugs for the treatment of chronic diseases.

Apart from pharmaceutical and biotechnology companies and academic and research institutes, contract manufacturing organizations (CMOs) and contract research organizations (CROs) also utilize peptides in large quantities. These entities require a wide range of reagents and equipment to synthesize peptides for antibody production, enzyme profiling, drug discovery, disease research, and biomarker discovery. The reagents utilized by them for the synthesis of peptides include precipitation agents, additives, substrates, and buffers, while the advanced platforms being used for the purpose include the PepTrend system.

According to P&S Intelligence, the Asia-Pacific customized peptide synthesis market will exhibit the fastest growth in the foreseeable future. This will be due to the high-volume usage of peptides in drug discovery, constant technological innovations, hefty R&D funding, and low cost of raw materials in the region. Drug manufacturers in APAC countries are racing to meet the growing requirement for peptide-based drugs to treat chronic diseases. Additionally, new research findings in the region will offer lucrative opportunities for the discovery of peptide-based drugs in the coming years.

Thus, the continuous technological advancements and hefty investments in R&D will lead to a significant rise in the peptide designing and synthesizing activities in the coming years.

Read More

Boom Predicted in Worldwide Sales of Practice Management Systems in Future Years

 The rapid establishment of several small and medium hospitals in various countries such as the U.S. is causing a sharp surge in the worldwide demand for practice management systems. As per the data published by the American Hospital Association (AHA) in 2018, there were over 5,500 hospitals in the U.S as of 2018. Out of these, around 2,500 were non-profit organizations. Besides this, the soaring healthcare costs in many countries are also fueling the demand for practice management systems.

Get More Information Practice Management Systems Market Analysis

Both developed and developing countries are heavily struggling in implementing quality and cost-effective healthcare for their citizens. Despite the availability of insurance programs and surging healthcare expenditure, the healthcare costs are soaring rapidly and making it very difficult for healthcare providers to deliver quality medical care at affordable prices. As practice management systems allow medical practitioners to provide quality treatment at affordable prices, the surging healthcare costs are propelling their sales across the globe.

This is subsequently fueling the expansion of the global practice management systems market. Software and services are the major components of practice management systems. Between these, the demand for software was observed to be higher during the last few years, primarily because of its large-scale adoption for patient engagement solutions, e-prescriptions, and electronic health records (EHR). Furthermore, the customized of practice management system software is quickly becoming a popular global trend.

This is credited to the fact that these systems offer higher administrative and clinical efficiency than the standalone ones. Web-based, cloud-based, and on-premise based are the most widely used types of delivery modes for practice management systems. Amongst these, the demand for cloud-based delivery mode will skyrocket in the upcoming years. This will be because the cloud-based practice management systems have achieved Health Insurance Portability and Accountability Act (HIPAA) compliance via data centers with high-level encryption methods and bank-level security.

Hence, it can be said with full confidence that the demand for practice management systems will shoot up across the world in the future years, mainly because of the increasing number of small and medium-sized hospitals in several countries and the growing requirement for cost-effective healthcare and medical treatment.

Read More